Breast Cancer Vaccine Shows Promise in Mid-Stage Trial
Compound activates immune cells (February 12)
Promising results have been reported from a phase II study of an investigational cancer vaccine (AE37) designed to prevent relapse in patients who have had breast cancer. The new findings corroborate results from an interim analysis conducted in October 2011.
Specifically, the more prevalent population of breast cancer patients ineligible to receive trastuzumab (Herceptin, Genentech) and particularly those in high-risk groups (e.g., triple-negative breast cancer), appear to benefit most from AE37. According to the vaccine’s developer (Generex Biotechnology), both of these patient populations represent areas of significant unmet need.
Full results from the study will be presented at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 30 to June 3 in Chicago.
The AE37 cancer vaccine is designed to work indirectly by stimulating the patient’s immune system to recognize and kill cancer cells. A potential advantage of the compound is that it activates a subclass of immune cells, known as CD4+ T cells, without sacrificing tumor-target specificity. AE37 consists of a fragment of the tumor-associated human epidermal growth factor receptor 2 (HER2) protein modified by a proprietary platform technology.
Source: Generex Biotechnology; February 12, 2014.